HK Stock Market Move | INNOGEN-B(02591) opened more than 13% higher; core product efsubaglutide alfa goes overseas, with potential contract value exceeding US$1 billion.

date
09:27 20/11/2026
avatar
GMT Eight
INNOGEN-B(02591) opened more than 13% higher. As of press time, it was up 13.05% at HK$3.595, with a turnover of HK$1.6789 million.
INNOGEN-B(02591) opened more than 13% higher, up 13.05% as of press time at HK$3.595, with turnover of HK$1.6789 million. On the news front, on November 19, Innogen Pharma announced that the company has signed an exclusive licensing agreement with Arcera Life Sciences Ltd. to advance the development and commercialization of efsubaglutide alfa, an innovative product independently developed by Innogen Pharma, in emerging markets worldwide. Under the agreement, Arcera will obtain exclusive rights to efsubaglutide alfa in Africa, Latin America, the Middle East and some countries in Eastern Europe, while Innogen Pharma retains the relevant rights in the rest of the world. Innogen Pharma will receive US$38 million in upfront and near-term milestone payments (including a non-refundable US$15 million upfront payment) as well as double-digit royalties, for a total potential contract value of more than US$1 billion. The company said this collaboration marks an important breakthrough for a Chinese-developed, already-commercialized innovative GLP-1 drug going overseas, and will further advance the implementation of Innogen Pharma's internationalization strategy.